English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Distinguishing endocervical adenocarcinoma (ECA) from endometrial adenocarcinoma (EMA) is clinically significant and cannot always be made on the basis of morphology alone or clinical findings. The aim of this study was to study the potential utility of ProExC as a new marker for cervical adenocarcinoma, and to evaluate a panel of monoclonal antibodies composed of p16, ER, PR, and vimentin, and assess their diagnostic value in distinguishing between ECA and EMA.

ProExC is a novel marker for distinguishing between primary endometrial and endocervical adenocarcinomas